Tools & Techniques: Screening siRNA Delivery Nanoparticles; Reporter Model for siRNA PD; and More | GenomeWeb

In an effort to improve the screening and selection of lipid nanoparticle delivery vehicles for siRNA therapeutics, researchers from Merck have developed an in vitro assay designed to test how the particles will behave in vivo.

After systemic administration, lipid nanoparticles are exposed to a variety of biological elements such as serum proteins and blood proteins that can affect their ability to effectively carry RNAi payloads to target tissues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.